InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,195.29
(
0.28%
)
US TECH 100
17,662.40
(
0.30%
)
Dow Jones
38,931.26
(
0.20%
)
Brent Oil
82.91
(
-0.68%
)
Bitcoin
63,734.83
(
0.90%
)
Post# of 36558
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Rubberneck2

Send PM Follow Ignore
Followers 6
Posts 1286
Boards Moderated 0
Alias Born 07/20/2020

Rubberneck2

Re: None

Monday, 02/01/2021 12:16:04 PM

Monday, February 01, 2021 12:16:04 PM

Post# of 36558
Can someone clarify this for me - Revive Therapeutics Patent Portfolio and Product Pipeline - Bucillamine in the treatment of Infectious diseases, including COVID-19.

My question is - When we complete the phase 3 trials for Covid, does the drug then have to go through separate trials for its use in treating other infectious diseases i.e. flu, COVID 20, etc or what’s the deal?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
InvestorsHub NewsWire

FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM

Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Start posting your company's news
Only $200 per official company press release!